Rheumatoid Arthritis Drug Baricitinib Linked to Reduced Mortality in COVID-19 Patients – Cath Lab Digest

November 13, 2020 The rheumatoid arthritis drug baricitinib can block viral entry and reduce mortality in patients with moderate to severe COVID-19, according to translational research by an international team coordinated by researchers from Karolinska Institutet in Sweden. The findings, published in the journal Science Advances, support the continuation of ongoing randomized clinical trials.
We are pleased to report a 71 percent reduction in mortality for the group receiving baricitinib in addition…

Click here to view the original article.